Molecular genesis of drug-resistant and vaccine-escape HBV mutants
- PMID: 20516565
- DOI: 10.3851/IMP1499
Molecular genesis of drug-resistant and vaccine-escape HBV mutants
Abstract
A high rate of viral turnover, combined with an error-prone polymerase, results in a very high frequency of mutational events during HBV replication. Not surprisingly, particular selection pressures, both endogenous (host immune clearance) and exogenous (vaccines and antivirals), readily select out new 'escape' mutants. The introduction of nucleoside/nucleotide analogue (NA) therapy for chronic hepatitis B has witnessed the emergence of antiviral drug resistance as the major factor limiting drug efficacy. Furthermore, because of the overlap of the viral polymerase and envelope reading frames in the HBV DNA genome, NA resistance-associated mutations selected in the catalytic domains of the polymerase frequently result in important changes to the neutralizing antibody-binding domains of the hepatitis B surface antigen, including the emergence of antiviral drug-associated potential vaccine escape mutants (ADAPVEMs). The public health significance of ADAPVEMs is considerable in terms of the global programme for control of hepatitis B via universal infant immunization. Thus, prevention of resistance requires the adoption of strategies that not only effectively control HBV replication, but also prevent the emergence of ADAPVEMs.
Similar articles
-
Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.Antivir Ther. 2007;12 Suppl 3:H15-23. Antivir Ther. 2007. PMID: 18284179 Review.
-
Potential threat of drug-resistant and vaccine-escape HBV mutants to public health.Antivir Ther. 2010;15(3 Pt B):445-9. doi: 10.3851/IMP1556. Antivir Ther. 2010. PMID: 20516564
-
Antiviral drug-associated potential vaccine-escape hepatitis B virus mutants in Turkish patients with chronic hepatitis B.Int J Infect Dis. 2011 Oct;15(10):e722-6. doi: 10.1016/j.ijid.2011.05.019. Epub 2011 Jul 23. Int J Infect Dis. 2011. PMID: 21784687
-
Molecular virology and the development of resistant mutants: implications for therapy.Semin Liver Dis. 2005;25 Suppl 1:9-19. doi: 10.1055/s-2005-915645. Semin Liver Dis. 2005. PMID: 16103977 Review.
-
Drug-resistant and immune-escape HBV mutants in HIV-infected hosts.Antivir Ther. 2010;15(3 Pt B):493-7. doi: 10.3851/IMP1495. Antivir Ther. 2010. PMID: 20516570 Review.
Cited by
-
Hepatitis B Virus (HBV) Genotype Mixtures, Viral Load, and Liver Damage in HBV Patients Co-infected With Human Immunodeficiency Virus.Front Microbiol. 2021 Mar 3;12:640889. doi: 10.3389/fmicb.2021.640889. eCollection 2021. Front Microbiol. 2021. PMID: 33746932 Free PMC article.
-
A review on potential of natural products in the management of COVID-19.RSC Adv. 2021 May 12;11(27):16711-16735. doi: 10.1039/d1ra00644d. eCollection 2021 Apr 30. RSC Adv. 2021. PMID: 35479175 Free PMC article. Review.
-
Molecular biology of the hepatitis B virus for clinicians.J Clin Exp Hepatol. 2012 Dec;2(4):353-65. doi: 10.1016/j.jceh.2012.10.003. Epub 2012 Oct 18. J Clin Exp Hepatol. 2012. PMID: 25755457 Free PMC article. Review.
-
Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1.Lancet Infect Dis. 2012 Dec;12(12):966-76. doi: 10.1016/S1473-3099(12)70243-8. Lancet Infect Dis. 2012. PMID: 23174382 Free PMC article. Review.
-
Prevalence and molecular characterization of occult hepatitis B virus in pregnant women from Gondar, Ethiopia.Can Liver J. 2020 Nov 17;3(4):323-333. doi: 10.3138/canlivj-2019-0031. eCollection 2020 Fall. Can Liver J. 2020. PMID: 35990510 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
